Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

UK lawmakers call for PM Johnson to publish big pharma lobbying messages

Published 04/25/2021, 07:43 PM
Updated 04/25/2021, 09:50 PM
© Reuters. Britain's PM Boris Johnson visits Hartlepool United Football Club ahead of May 6 by-election

By James Davey

LONDON, April 26 (Reuters) - British lawmakers on Monday called on the government to publish all communications with pharmaceutical companies to understand if private lobbying influenced its opposition to a waiver of intellectual property rules for COVID-19 vaccines.

The United States and a handful of other big countries, including the United Kingdom, have blocked negotiations at the World Trade Organization (WTO) involving a proposal spearheaded by India and South Africa that now has the support of 100 WTO members.

The proposal would temporarily waive the intellectual property (IP) rights of pharmaceutical companies to allow developing countries to produce vaccines.

The waiver is opposed by the U.S. Chamber of Commerce and big pharmaceutical companies such as Pfizer (NYSE:PFE) PFE.N, BioNTech 22UAy.DE, Moderna (NASDAQ:MRNA) MRNA.O, and Johnson & Johnson (NYSE:JNJ) JNJ.N.

A cross-party group of UK lawmakers has signed a statement calling for Prime Minister Boris Johnson, ministers, and senior civil servants to publish all email, text, and WhatsApp messages exchanged with pharmaceutical companies and their lobbyists.

Patient advocacy and vaccine equity organisations have also signed the statement, including Global Justice Now, Just Treatment, StopAIDS, Frontline (NYSE:FRO) AIDS, Universities Allied for Essential Medicines UK, Students for Global Health, and Nurses United UK.

"The UK's opposition to an intellectual property waiver on COVID-19 vaccines is utterly indefensible," said Heidi Chow, senior policy and campaigns manager at Global Justice Now, which organised the joint statement.

A spokesperson for the UK government said it prioritised transparency but stakeholders had a right to expect a reasonable degree of confidentiality in their communications.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The UK was one of the biggest donors to Covax to ensure global access to vaccines and continued to encourage manufacturers to provide their vaccines on a not-for-profit, transparent basis.

"We are committed to exploring ways in which we can improve equitable access further and believe this should be done through the existing Intellectual Property framework," added the spokesperson.

Last week U.S. lawmakers and nonprofit groups heaped pressure on the Biden administration to back the patent waiver ahead of the next formal WTO meeting on the issue on May 5.

(

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.